EpimAb Biotherap 
Welcome,         Profile    Billing    Logout  
  Products    Diseases    Products    Trials    News 
  • ||||||||||  EMB-06 / EpimAb Biotherap
    A Phase I Study of a Novel BCMA (Pacific Ballroom Salons 18-19 (Marriott Marquis San Diego Marina)) -  Nov 6, 2024 - Abstract #ASH2024ASH_2161;    
    In an ongoing first-in-human study in patients with advanced refractory solid tumors (NCT05263180), EMB-09 demonstrated a consistent pharmacodynamic response and early efficacy signals. In this analysis of full dose escalation study, EMB-06 demonstrated a differentiated safety profile in RRMM patients, with low rates of CRS and no ICANS, and durable efficacy in heavily pre-treated RRMM patients.
  • ||||||||||  bafisontamab (EMB-01) / EpimAb Biotherap
    Trial completion date, Trial primary completion date, Metastases:  EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers (clinicaltrials.gov) -  Aug 14, 2024   
    P1/2,  N=152, Recruiting, 
    Ethics Approval All animal studies were conducted under approval of the Shanghai Yishang Biotech committee on animal care in accordance with local guidelines. Trial completion date: Aug 2024 --> Dec 2025 | Trial primary completion date: Aug 2024 --> Dec 2025
  • ||||||||||  EMB-02 / EpimAb Biotherap
    Trial completion date, Trial termination, Trial primary completion date, Metastases:  A Study of EMB-02 in Participants With Advanced Solid Tumors (clinicaltrials.gov) -  May 21, 2024   
    P1/2,  N=47, Terminated, 
    Trial completion date: Aug 2024 --> Dec 2025 | Trial primary completion date: Aug 2024 --> Dec 2025 Trial completion date: Dec 2025 --> Mar 2024 | Recruiting --> Terminated | Trial primary completion date: Dec 2023 --> Jul 2023; Company's resource optimization and product's development change
  • ||||||||||  EMB-06 / EpimAb Biotherap
    A phase I study of a novel BCMA (Exhibits Hall B) -  Oct 25, 2023 - Abstract #SITC2023SITC_1916;    
    P1/2
    An initial ORR of 100% has been observed at doses ?120mg. Updated data will be shared at the meeting.
  • ||||||||||  bafisontamab (EMB-01) / EpimAb Biotherap
    Trial completion date, Trial primary completion date, Metastases:  A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors (clinicaltrials.gov) -  May 31, 2023   
    P1/2,  N=186, Recruiting, 
    Expansion cohorts in select advanced solid tumours are ongoing. Trial completion date: Mar 2023 --> Jan 2026 | Trial primary completion date: Mar 2023 --> Mar 2025
  • ||||||||||  bafisontamab (EMB-01) / EpimAb Biotherap
    Trial initiation date, Combination therapy, Metastases:  EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer (clinicaltrials.gov) -  Feb 21, 2023   
    P1/2,  N=115, Not yet recruiting, 
    Trial completion date: Mar 2023 --> Jan 2026 | Trial primary completion date: Mar 2023 --> Mar 2025 Initiation date: Oct 2022 --> Jun 2023
  • ||||||||||  EMB-02 / EpimAb Biotherap, EMB-01 / EpimAb Biotherap
    Unique Properties and Clinical Progress of Leading FIT-Ig-Based Bispecific Antibodies (306) -  Apr 24, 2022 - Abstract #PEGS2022PEGS_493;    
    Based on FIT-Ig, EpimAb's bispecific antibody technology, a number of therapeutic molecules have been developed and several are in clinical development, including cancer cell targeting cMET/EGFR (EMB-01) and dual check-point PD-1/LAG-3 (EMB-02). Current data reveals more aspects concerning the clinical validation of the FIT-Ig technology, as well as the synergistic mechanism of these dual-targeting bispecific antibodies.
  • ||||||||||  EMB-01 / EpimAb Biotherap
    EMB-01: An EGFR-cMET bispecific antibody, in advanced/metastatic solid tumors phase I results ([VIRTUAL]) -  Feb 19, 2022 - Abstract #ELCC2022ELCC_295;    
    P1/2
    Preliminary anti-tumor evidence suggests EMB-01 can have activity in EGFR driven NSCLC, including pts with acquired EGFR TKI resistance and EGFR exon20ins mutations. The expansion phase (Ph II) is currently enrolling biomarker selected NSCLC pts with EGFR and/or cMET aberrations as identified by next-generation sequencing in circulating tumor DNA (ctDNA) and/or tumor tissue.
  • ||||||||||  bafisontamab (EMB-01) / EpimAb Biotherap
    Enrollment change, Trial completion date, Trial primary completion date, Metastases:  A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors (clinicaltrials.gov) -  Sep 5, 2021   
    P1/2,  N=186, Recruiting, 
    The expansion phase (Ph II) is currently enrolling biomarker selected NSCLC pts with EGFR and/or cMET aberrations as identified by next-generation sequencing in circulating tumor DNA (ctDNA) and/or tumor tissue. N=137 --> 186 | Trial completion date: Mar 2024 --> Mar 2023 | Trial primary completion date: Mar 2024 --> Mar 2023
  • ||||||||||  EMB-06 / EpimAb Biotherap
    Enrollment open:  A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma (clinicaltrials.gov) -  Aug 11, 2021   
    P1/2,  N=66, Recruiting, 
    N=137 --> 186 | Trial completion date: Mar 2024 --> Mar 2023 | Trial primary completion date: Mar 2024 --> Mar 2023 Not yet recruiting --> Recruiting
  • ||||||||||  EMB-02 / EpimAb Biotherap
    Enrollment status, Metastases:  A Study of EMB-02 in Participants With Advanced Solid Tumors (clinicaltrials.gov) -  Jan 21, 2021   
    P1/2,  N=43, Recruiting, 
    Not yet recruiting --> Recruiting Enrolling by invitation --> Recruiting
  • ||||||||||  EMB-02 / EpimAb Biotherap
    Enrollment open, Metastases:  A Study of EMB-02 in Participants With Advanced Solid Tumors (clinicaltrials.gov) -  Jan 19, 2021   
    P1/2,  N=43, Enrolling by invitation, 
    Enrolling by invitation --> Recruiting Not yet recruiting --> Enrolling by invitation